Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model.

Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med (2003) 7.40

Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis (2014) 5.60

Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med (2014) 5.23

Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med (2012) 4.69

WHO's new end TB strategy. Lancet (2015) 2.77

Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet (2015) 2.69

High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med (2014) 2.42

A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med (2014) 2.39

Tuberculosis treatment and management--an update on treatment regimens, trials, new drugs, and adjunct therapies. Lancet Respir Med (2015) 2.31

Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis (2014) 2.18

Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J (2012) 2.17

Linezolid for multidrug-resistant tuberculosis in HIV-infected and -uninfected patients. Eur Respir J (2015) 2.03

Reducing relapse in tuberculosis treatment: is it time to reassess WHO treatment guidelines? Int J Tuberc Lung Dis (2015) 2.00

Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J (2015) 1.95

Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med (2015) 1.86

Transmission of Multidrug-Resistant and Drug-Susceptible Tuberculosis within Households: A Prospective Cohort Study. PLoS Med (2015) 1.86

Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis. Lancet Respir Med (2015) 1.72

The impact of HIV/AIDS on the control of tuberculosis in India. Proc Natl Acad Sci U S A (2005) 1.41

Patient costs during tuberculosis treatment in Bangladesh and Tanzania: the potential of shorter regimens. Int J Tuberc Lung Dis (2014) 1.14

The high cost of free tuberculosis services: patient and household costs associated with tuberculosis care in Ebonyi State, Nigeria. PLoS One (2013) 1.08

A controlled trial of 2-month, 3-month, and 12-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 60 months. Am Rev Respir Dis (1984) 1.04

Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. Eur Respir J (2016) 0.90

The Potential Impact of Up-Front Drug Sensitivity Testing on India's Epidemic of Multi-Drug Resistant Tuberculosis. PLoS One (2015) 0.88

Shortening Tuberculosis Treatment With Fluoroquinolones: Lost in Translation? Clin Infect Dis (2015) 0.84

Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials. Eur Respir Rev (2016) 0.82

Later emergence of acquired drug resistance and its effect on treatment outcome in patients treated with Standard Short-Course Chemotherapy for tuberculosis. BMC Pulm Med (2016) 0.81

Safety and tolerability profile of second-line anti-tuberculosis medications. Drug Saf (2015) 0.80

Pharmacological interactions between rifampicin and antiretroviral drugs: challenges and research priorities for resource-limited settings. Ther Drug Monit (2015) 0.80

The Distribution of Fitness Costs of Resistance-Conferring Mutations Is a Key Determinant for the Future Burden of Drug-Resistant Tuberculosis: A Model-Based Analysis. Clin Infect Dis (2015) 0.78

Challenges of antituberculosis treatment in patients with difficult clinical conditions. Clin Respir J (2014) 0.77

Ending tuberculosis by 2030: can we do it? Int J Tuberc Lung Dis (2016) 0.76

Potential impact of spatially targeted adult tuberculosis vaccine in Gujarat, India. J R Soc Interface (2016) 0.77

MDR-TB treatment as prevention: The projected population-level impact of expanded treatment for multidrug-resistant tuberculosis. PLoS One (2017) 0.75

Comparing Drivers and Dynamics of Tuberculosis (TB) in California, Florida, New York and Texas. Am J Respir Crit Care Med (2017) 0.75